Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 24150220)

1.

Induction of differential apoptotic pathways in multiple myeloma cells by class-selective histone deacetylase inhibitors.

Hideshima T, Mazitschek R, Santo L, Mimura N, Gorgun G, Richardson PG, Raje N, Anderson KC.

Leukemia. 2014 Feb;28(2):457-60. doi: 10.1038/leu.2013.301. Epub 2013 Oct 22. No abstract available.

2.

Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.

Bai LY, Omar HA, Chiu CF, Chi ZP, Hu JL, Weng JR.

Cancer Chemother Pharmacol. 2011 Aug;68(2):489-96. doi: 10.1007/s00280-010-1501-z. Epub 2010 Nov 12.

PMID:
21072520
3.

Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC.

Mithraprabhu S, Khong T, Jones SS, Spencer A.

Br J Haematol. 2013 Aug;162(4):559-62. doi: 10.1111/bjh.12388. Epub 2013 May 21. No abstract available.

PMID:
23692150
4.
5.

The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells.

Mandl-Weber S, Meinel FG, Jankowsky R, Oduncu F, Schmidmaier R, Baumann P.

Br J Haematol. 2010 May;149(4):518-28. doi: 10.1111/j.1365-2141.2010.08124.x. Epub 2010 Mar 1.

PMID:
20201941
6.

Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways.

Doudican NA, Wen SY, Mazumder A, Orlow SJ.

Oncol Rep. 2012 Nov;28(5):1851-8. doi: 10.3892/or.2012.1977. Epub 2012 Aug 22.

7.

The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.

Baumann P, Junghanns C, Mandl-Weber S, Strobl S, Oduncu F, Schmidmaier R.

Br J Haematol. 2012 Mar;156(5):633-42. doi: 10.1111/j.1365-2141.2011.08983.x. Epub 2011 Dec 23.

PMID:
22211565
8.

Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors.

Dai Y, Chen S, Wang L, Pei XY, Funk VL, Kramer LB, Dent P, Grant S.

J Biol Chem. 2011 Sep 30;286(39):34036-50. doi: 10.1074/jbc.M111.284216. Epub 2011 Aug 4.

9.

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.

Feng R, Ma H, Hassig CA, Payne JE, Smith ND, Mapara MY, Hager JH, Lentzsch S.

Mol Cancer Ther. 2008 Jun;7(6):1494-505. doi: 10.1158/1535-7163.MCT-08-0183.

10.

Anacardic acid induces cell apoptosis associated with induction of ATF4-dependent endoplasmic reticulum stress.

Huang H, Hua X, Liu N, Li X, Liu S, Chen X, Zhao C, Lan X, Yang C, Dou QP, Liu J.

Toxicol Lett. 2014 Aug 4;228(3):170-8. doi: 10.1016/j.toxlet.2014.05.012. Epub 2014 May 20.

PMID:
24853302
11.

Arsenic trioxide exerts antimyeloma effects by inhibiting activity in the cytoplasmic substrates of histone deacetylase 6.

Qu X, Du J, Zhang C, Fu W, Xi H, Zou J, Hou J.

PLoS One. 2012;7(2):e32215. doi: 10.1371/journal.pone.0032215. Epub 2012 Feb 22.

12.

Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.

Sung ES, Kim A, Park JS, Chung J, Kwon MH, Kim YS.

Apoptosis. 2010 Oct;15(10):1256-69. doi: 10.1007/s10495-010-0521-9.

PMID:
20582477
14.

Brazilin induces apoptosis and G2/M arrest via inactivation of histone deacetylase in multiple myeloma U266 cells.

Kim B, Kim SH, Jeong SJ, Sohn EJ, Jung JH, Lee MH, Kim SH.

J Agric Food Chem. 2012 Oct 3;60(39):9882-9. doi: 10.1021/jf302527p. Epub 2012 Sep 21.

PMID:
22967175
15.

Panobinostat synergizes with bortezomib to induce endoplasmic reticulum stress and ubiquitinated protein accumulation in renal cancer cells.

Sato A, Asano T, Isono M, Ito K, Asano T.

BMC Urol. 2014 Aug 30;14:71. doi: 10.1186/1471-2490-14-71.

16.

Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma.

Cheriyath V, Kuhns MA, Kalaycio ME, Borden EC.

Br J Cancer. 2011 Mar 15;104(6):957-67. doi: 10.1038/bjc.2011.42. Epub 2011 Mar 1.

17.
18.
19.

Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.

Tagoug I, Jordheim LP, Herveau S, Matera EL, Huber AL, Chettab K, ManiƩ S, Dumontet C.

Clin Cancer Res. 2013 Jul 1;19(13):3556-66. doi: 10.1158/1078-0432.CCR-12-3134. Epub 2013 May 14.

20.

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, Cirstea D, Rodig S, Eda H, Scullen T, Canavese M, Bradner J, Anderson KC, Jones SS, Raje N.

Blood. 2012 Mar 15;119(11):2579-89. doi: 10.1182/blood-2011-10-387365. Epub 2012 Jan 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk